drugset / Trial / NCT04502472

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472

Phase 2/3 Terminated 109 enrolled Inova Health Care Services
NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.

Timeline

Start
2020-06-06
Primary completion
2020-09-30
Completion
2020-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic

Indications